Handelsbanken Fonder AB increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 590,156 shares of the biopharmaceutical company's stock after acquiring an additional 51,453 shares during the period. Handelsbanken Fonder AB's holdings in Gilead Sciences were worth $54,513,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Avior Wealth Management LLC grew its position in Gilead Sciences by 1.2% in the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock valued at $782,000 after purchasing an additional 108 shares in the last quarter. Southland Equity Partners LLC grew its position in Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock valued at $289,000 after purchasing an additional 110 shares in the last quarter. Concord Asset Management LLC VA grew its position in Gilead Sciences by 3.8% in the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company's stock valued at $256,000 after purchasing an additional 111 shares in the last quarter. Berkshire Bank grew its position in Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after purchasing an additional 111 shares in the last quarter. Finally, TFB Advisors LLC grew its position in Gilead Sciences by 1.2% in the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company's stock valued at $788,000 after purchasing an additional 116 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares of the company's stock, valued at $815,198.80. The trade was a 43.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 713,000 shares of company stock worth $67,945,181. 0.16% of the stock is currently owned by corporate insiders.
Gilead Sciences Stock Performance
Gilead Sciences stock traded down $0.08 during midday trading on Friday, hitting $109.95. The company's stock had a trading volume of 9,729,048 shares, compared to its average volume of 7,379,648. The company has a 50-day moving average price of $95.41 and a two-hundred day moving average price of $88.73. The company has a market cap of $137.03 billion, a price-to-earnings ratio of 297.16, a PEG ratio of 0.71 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $111.03.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. Gilead Sciences's payout ratio is presently 832.43%.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on GILD shares. Citigroup started coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They issued a "buy" rating and a $125.00 target price for the company. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Piper Sandler lifted their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Finally, Truist Financial lifted their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research report on Friday, November 8th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $102.08.
Read Our Latest Research Report on Gilead Sciences
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
